Want to see VRDN full AI Analyst Report?
VRDN Stock Chart & Stats
$19.27
<$0.01(0.05%)
At close: 4:00 PM EDT
$19.27
<$0.01(0.05%)
Day’s Range― - ―
52-Week Range$13.18 - $34.29
Previous Close$19.2
Volume1.52M
Average Volume (3M)2.23M
Market Cap
$2.75B
Enterprise Value$1.34K
Total Cash (Recent Filing)$981.53M
Total Debt (Recent Filing)$242.88M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 16, 2026EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.53
Shares Outstanding113,292,270
10 Day Avg. Volume1,692,252
30 Day Avg. Volume2,232,459
Financial Highlights & Ratios
PEG Ratio0.57
Price to Book (P/B)3.65
Price to Sales (P/S)37.25
P/FCF Ratio-9.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$34.00Price Target Upside76.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.82
Revenue Forecast (FY)$21.42M
Bulls Say, Bears Say
Bulls Say
Lumvoa Commercial LaunchThe move into commercial operations creates a potential recurring revenue base beyond financing. Early physician, patient and payer feedback supports adoption prospects, although the launch remains at an early stage and will require sustained execution.
Strong LiquidityA substantial liquidity position gives Viridian resources to fund commercialization and clinical development while reducing near-term dependence on capital markets. This strengthens operating flexibility during the transition toward potential profitability.
Scalable Manufacturing ReadinessSecuring a qualified commercial manufacturing partner ahead of approval can reduce execution risk and support scalable supply. The ability to use alternate manufacturers also provides flexibility if capacity, regulatory or operational conditions change.
Bears Say
Large Ongoing LossesViridian remains substantially unprofitable despite higher revenue, as operating expenses continue to outweigh gross profit. Persistent losses could delay self-sustaining operations and require continued cost control, funding or successful product scaling.
Heavy Cash BurnDeeply negative operating and free cash flow show that the business is not yet funding itself. Continued investment in launch activities and pipeline programs may consume liquidity materially before commercial revenues can support ongoing expenditure.
Approval And Execution DependenceFuture growth depends on successful commercialization of Lumvoa and regulatory approval of pipeline programs. Delays, unsuccessful development or weaker adoption would extend losses and reduce the likelihood that projected revenues fund the business through profitability.
Viridian Therapeutics News
VRDN FAQ
What was Viridian Therapeutics, Inc.’s price range in the past 12 months?
Viridian Therapeutics, Inc. lowest stock price was $13.18 and its highest was $34.29 in the past 12 months.
What is Viridian Therapeutics, Inc.’s market cap?
Viridian Therapeutics, Inc.’s market cap is $2.75B.
When is Viridian Therapeutics, Inc.’s upcoming earnings report date?
Viridian Therapeutics, Inc.’s upcoming earnings report date is Nov 16, 2026 which is in 85 days.
How were Viridian Therapeutics, Inc.’s earnings last quarter?
Viridian Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$1.035 by -$0.015.
Is Viridian Therapeutics, Inc. overvalued?
According to Wall Street analysts Viridian Therapeutics, Inc.’s price is currently Undervalued.
Does Viridian Therapeutics, Inc. pay dividends?
Viridian Therapeutics, Inc. does not currently pay dividends.
What is Viridian Therapeutics, Inc.’s EPS estimate?
Viridian Therapeutics, Inc.’s EPS estimate is -0.99.
How many shares outstanding does Viridian Therapeutics, Inc. have?
Viridian Therapeutics, Inc. has 113,292,270 shares outstanding.
What happened to Viridian Therapeutics, Inc.’s price movement after its last earnings report?
Viridian Therapeutics, Inc. reported an EPS of -$1.05 in its last earnings report, missing expectations of -$1.035. Following the earnings report the stock price went up 6.834%.
Which hedge fund is a major shareholder of Viridian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in VRDN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viridian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.00 (76.44% Upside)
$34.00 (76.44% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 957.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $348.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 7.4%
Last 30 Days ▼ 7.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
88.42%
Trailing 12-Months
Company Description
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. (VRDN) is a clinical-stage biotechnology company focused on developing potential treatments for thyroid eye disease (TED) and related autoimmune conditions. The company’s pipeline includes investigational monoclonal antibody candidates designed to inhibit insulin-like growth factor-1 receptor (IGF-1R), with programs such as VRDN-001 and VRDN-003 aimed at improving outcomes and dosing convenience for patients with TED. Viridian operates in the biotechnology/pharmaceutical sector and is primarily engaged in research and development rather than commercial product sales.
VRDN Stock 12 Month Forecast
Average Price Target
$34.00
▲(76.44% Upside)
Technical Analysis
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
4.58% Insiders
25.59% Mutual Funds
52.73% Other Institutional Investors
1.73% Public Companies and
Individual Investors